Prescription Drug User Fee Act action date is September 26, 2024
If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades
The.
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treat.
Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia
KarXT demonstrated a mean change from baseline to week 8 in 24-hour.
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of .